ATE248599T1 - Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen - Google Patents

Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen

Info

Publication number
ATE248599T1
ATE248599T1 AT00910789T AT00910789T ATE248599T1 AT E248599 T1 ATE248599 T1 AT E248599T1 AT 00910789 T AT00910789 T AT 00910789T AT 00910789 T AT00910789 T AT 00910789T AT E248599 T1 ATE248599 T1 AT E248599T1
Authority
AT
Austria
Prior art keywords
neuropoisoning
xenon
preparing
treatment
pharmaceutical composition
Prior art date
Application number
AT00910789T
Other languages
English (en)
Inventor
Christian Petzelt
Wolfgang J Kox
Original Assignee
Aga Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7900688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE248599(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aga Ab Publ filed Critical Aga Ab Publ
Application granted granted Critical
Publication of ATE248599T1 publication Critical patent/ATE248599T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00910789T 1999-03-11 2000-03-08 Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen ATE248599T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910986A DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen
PCT/EP2000/002025 WO2000053192A1 (en) 1999-03-11 2000-03-08 Use of xenon for treating neurointoxications

Publications (1)

Publication Number Publication Date
ATE248599T1 true ATE248599T1 (de) 2003-09-15

Family

ID=7900688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910789T ATE248599T1 (de) 1999-03-11 2000-03-08 Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen

Country Status (29)

Country Link
US (3) US6559190B1 (de)
EP (1) EP1158992B2 (de)
JP (1) JP4954373B2 (de)
KR (1) KR100674407B1 (de)
CN (1) CN1170544C (de)
AR (1) AR022886A1 (de)
AT (1) ATE248599T1 (de)
AU (1) AU757361B2 (de)
BG (1) BG105889A (de)
BR (1) BR0010456A (de)
CA (1) CA2367136C (de)
CZ (1) CZ302864B6 (de)
DE (2) DE19910986C2 (de)
DK (1) DK1158992T3 (de)
EE (1) EE200100480A (de)
ES (1) ES2206202T5 (de)
HK (1) HK1048073B (de)
HU (1) HUP0201393A3 (de)
IL (2) IL145177A0 (de)
MD (1) MD2935C2 (de)
NO (1) NO20014379L (de)
PL (1) PL202941B1 (de)
PT (1) PT1158992E (de)
RS (1) RS49756B (de)
RU (1) RU2246949C2 (de)
SI (1) SI1158992T1 (de)
SK (1) SK285111B6 (de)
WO (1) WO2000053192A1 (de)
ZA (1) ZA200107291B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
DE10045829A1 (de) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile Anästhesiemittel mit Xenon
DE10054563A1 (de) * 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
US20020102211A1 (en) * 2000-12-07 2002-08-01 Renshaw Perry F. Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
CN1668315A (zh) 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
EP1521598A1 (de) * 2002-07-05 2005-04-13 Air Liquide Deutschland GmbH Xenon enthaltendes adjuvans
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7681572B2 (en) 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
US7337776B2 (en) 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
AU2004280118B2 (en) 2003-10-10 2009-01-15 Imperial Innovations Limited Use of xenon with hypothermia for treating neonatal asphyxia
WO2005039600A2 (en) * 2003-10-21 2005-05-06 Aga Ab Use of xenon for the prevention of programmed cell death
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
EP1552840A1 (de) * 2004-01-07 2005-07-13 Aga Ab Mischung aus Xenon und Kohlenmonoxyd zum Schutz von Zellen
US7070005B2 (en) * 2004-02-10 2006-07-04 Planetair Turf Products, Llc Soil aerator assembly
WO2006017524A2 (en) * 2004-08-02 2006-02-16 Olney John W Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
WO2007075100A1 (en) * 2005-12-27 2007-07-05 Zakrytoe Aktsionernoe Obshchestvo 'atom-Med Center' Method for treating drug dependence
EP1980260A1 (de) * 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
US8435569B2 (en) 2007-04-30 2013-05-07 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
WO2010035074A1 (en) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Use of nitrous oxide, argon, xenon, helium, or neon, for the manufacture of a pharmaceutical composition for treating ischemic insults in patients who cannot be treated with thrombolytic agents
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
WO2011081612A1 (ru) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Применение криптона или ксенона в качестве противовирусного средства
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
FR2960779A1 (fr) 2010-06-08 2011-12-09 Air Liquide Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques
FR2964036B1 (fr) 2010-08-24 2013-04-12 Air Liquide Medicament gazeux inhalable a base de krypton pour le traitement des neuro-intoxications
RU2583179C2 (ru) 2011-02-07 2016-05-10 ЭДВАНСТ ПРЕЗЕРВЕЙШНЗ ТЕКНОЛОДЖИЗ, ЭлЭлСи Способ консервации клеток и культур клеток
FR2975597B1 (fr) * 2011-05-24 2013-12-27 Air Liquide Utilisation de neon pour le traitement des neuro-intoxications, notamment des maladies enurodegeneratives et demyelinisantes
JP6046727B2 (ja) 2011-09-26 2016-12-21 アドバンスド プリザベイションズ テクノロジーズ リミテッド ライアビリティー カンパニー 生体組織の保存方法
RU2489154C1 (ru) * 2012-05-31 2013-08-10 Сергей Александрович Наумов Способ лечения вирусных гепатитов
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
FR2996457B1 (fr) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Utilisation d'argon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996458B1 (fr) * 2012-10-09 2015-02-27 Air Liquide Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996459B1 (fr) * 2012-10-09 2015-02-06 Air Liquide Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
EP4082552B1 (de) 2013-03-15 2026-05-06 The Board of Regents of the University of Texas System Edelgasreiche flüssigkeiten sowie verfahren zu deren herstellung und verwendung
FR3007983B1 (fr) * 2013-07-08 2015-06-26 Air Liquide Association de xenon et d'un antagoniste des recepteurs nmda pour lutter contre une maladie neurodegenerative
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
FR3027226B1 (fr) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude Medicament pour traiter une maladie liee a un dysfonctionnement de la transmission synaptique dopaminergique
JP6622822B2 (ja) * 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
US20180318338A1 (en) * 2015-11-09 2018-11-08 The Mclean Hospital Corporation Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
US20170341980A1 (en) * 2016-05-31 2017-11-30 Noblis Therapeutics, Inc. Noble gas neuroprotection and neuroregeneration from treatment related neurotoxicity
US10485825B2 (en) * 2016-08-29 2019-11-26 Nobilis Therapeutics, Inc. Prevention of pregnancy complications by noble gas administration
RU2019116383A (ru) * 2016-10-31 2020-11-30 Нобилис Терапьютикс, Инк. Лечение тревожных расстройств и усиление противотревожных воздействий с помощью применения смесей, содержащих инертный газ
CN107569509B (zh) * 2017-02-22 2018-09-21 滨州医学院 氙或氙气体混合物在制备治疗癫痫的制剂中的用途
CN108986622A (zh) * 2018-08-16 2018-12-11 广州迈普再生医学科技股份有限公司 一种颅内血肿微创穿刺清除术培训装置及其制备方法
RU2712804C1 (ru) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Способ коррекции функционального состояния человека в замкнутом пространстве
RU2789964C1 (ru) * 2022-04-01 2023-02-14 Александр Юрьевич Верховский Способ улучшения состояния кожи и подкожных тканей

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5228434A (en) * 1991-07-16 1993-07-20 Praxair Technology, Inc. Mixture for anesthesia
US5357959A (en) * 1993-04-16 1994-10-25 Praxair Technology, Inc. Altered dipole moment magnetic resonance imaging method
AU688515B2 (en) * 1994-05-24 1998-03-12 F. Hoffmann-La Roche Ag Tricyclic dicarbonyl derivatives
RU2072241C1 (ru) * 1995-09-20 1997-01-27 Панина Елена Владимировна Способ формирования дыхательной газовой смеси и аппарат для его осуществления
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
IT1286058B1 (it) * 1996-10-29 1998-07-07 Siad Societa Italiana Acetilen Procedimento e apparecchiatura per la purificazione e recupero dello xeno e altri gas nobili in sistemi anestetici
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19823606C2 (de) * 1998-05-27 2002-02-28 Draeger Medical Ag Verwendung von Perfluorcarbone in einem Atemgasgemisch sowie die Vorrichtung
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
PL350618A1 (en) 2003-01-27
PT1158992E (pt) 2004-01-30
US8143317B2 (en) 2012-03-27
HUP0201393A2 (en) 2002-09-28
SI1158992T1 (en) 2004-02-29
SK285111B6 (sk) 2006-06-01
EP1158992B1 (de) 2003-09-03
CN1359296A (zh) 2002-07-17
HUP0201393A3 (en) 2002-10-28
AU3287500A (en) 2000-09-28
SK12792001A3 (sk) 2002-07-02
EP1158992A1 (de) 2001-12-05
PL202941B1 (pl) 2009-08-31
CN1170544C (zh) 2004-10-13
AR022886A1 (es) 2002-09-04
MD2935B2 (en) 2005-12-31
NO20014379L (no) 2001-11-07
HK1048073A1 (en) 2003-03-21
YU65401A (sh) 2004-07-15
AU757361B2 (en) 2003-02-20
JP4954373B2 (ja) 2012-06-13
KR20010108338A (ko) 2001-12-07
ZA200107291B (en) 2003-02-26
MD2935C2 (ro) 2006-08-31
WO2000053192A1 (en) 2000-09-14
KR100674407B1 (ko) 2007-01-26
IL145177A0 (en) 2002-06-30
DE60004974D1 (de) 2003-10-09
BG105889A (bg) 2002-04-30
EE200100480A (et) 2002-12-16
CZ302864B6 (cs) 2011-12-21
DE60004974T2 (de) 2004-07-22
DE60004974T3 (de) 2012-06-28
IL145177A (en) 2006-10-31
BR0010456A (pt) 2002-08-27
US6559190B1 (en) 2003-05-06
MD20010349A (en) 2002-02-28
CA2367136A1 (en) 2000-09-14
DE19910986A1 (de) 2000-09-21
EP1158992B2 (de) 2012-02-01
HK1048073B (zh) 2005-06-03
JP2002538209A (ja) 2002-11-12
DE19910986C2 (de) 2001-06-07
US20030180375A1 (en) 2003-09-25
ES2206202T5 (es) 2012-05-22
CA2367136C (en) 2008-05-13
DK1158992T3 (da) 2003-12-29
ES2206202T3 (es) 2004-05-16
RS49756B (sr) 2008-04-04
NO20014379D0 (no) 2001-09-10
CZ20013234A3 (cs) 2002-06-12
RU2246949C2 (ru) 2005-02-27
US20070110821A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE19983486T1 (de) Verfahren zur Herstellung von Citalopram
DE69906389D1 (de) Verfahren zur herstellung von citalopram
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
DE60112431D1 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
DE60024960D1 (de) Kontinuierliches Verfahren zur Herstellung von Siliconharzen
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE60024372D1 (de) Verfahren zur Herstellung von Tetraorganooxysilanen
DE50012014D1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DE60002254T2 (de) Verfahren zur Herstellung von 4,6-diaminoresorcin
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE69901243D1 (de) Artikulator zur herstellung von zahnärztlichen prothesen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin
DE69935355D1 (de) Verfahren zur Herstellung von Citalopram
DE60031231D1 (de) Verfahren zur Herstellung von 2-Alkyl-4-Isothiazolin-3-onen
DE60019763D1 (de) Verfahren zur herstellung von thiazolderivaten
DE60004119D1 (de) Verfahren zur Herstellung von Pentaacetyl-beta-D-Glucopyranose
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1158992

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee